Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05277753
PHASE1

NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL

Sponsor: Shenzhen Geno-Immune Medical Institute

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine the feasibility, safety, and efficacy of a combination therapy in the treatment of T-cell acute lymphoblastic leukemia (T-ALL): multi-antigen-targeted chimeric antigen receptor T cells (CAR-T) followed by engineered immune effector cytotoxic T cells (CTLs) and immune modified dendritic cell vaccine (DCvac). This approach is aimed to achieve NGS MRD negativity in T-ALL patients, which can identify a very low risk of relapse and define patients with possible long-term remission without further treatment.

Official title: NGS-MRD Evaluation of Antigen-specific T Cells and DC Vaccine Combination Targeting T-cell Acute Lymphoblastic Leukemia

Key Details

Gender

All

Age Range

6 Months - 65 Years

Study Type

INTERVENTIONAL

Enrollment

10

Start Date

2026-06-01

Completion Date

2030-12-31

Last Updated

2026-06-23

Healthy Volunteers

No

Interventions

BIOLOGICAL

Antigen-specific T cells CAR-T/CTL and DCvac

Antigen-specific T cells CAR-T/CTL and DCvac cells to treat T-ALL

Locations (1)

Shenzhen Geno-immune Medical Institute

Shenzhen, Guangdong, China